Bortezomib may Stabilize Pediatric Renal Transplant Recipients with Antibody-Mediated Rejection

BACKGROUND: Current therapeutic strategies to effectively treat antibody-mediated rejection (AMR) are insufficient. Thus, we aimed to determine the benefit of a therapeutic protocol using bortezomib for refractory C4d+ AMR in pediatric kidney transplant patients. METHODS: We examined 7 patients with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Nephrol
Autors principals: Pearl, Meghan H., Nayak, Anjali B., Ettenger, Robert B., Puliyanda, Dechu, Diaz, Miguel Fernando Palma, Zhang, Qiuheng, Reed, Elaine F., Tsai, Eileen W.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5590841/
https://ncbi.nlm.nih.gov/pubmed/27048228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-016-3319-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars